Characterization and localization of Ac-SDKP receptor binding sites using125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 2, 2007, Pages

  Zhuo, Jia L ^a,c   Carretero, Oscar A ^a   Peng, Hongmei ^a   Li, Xiao C ^a   Regoli, Domenico ^b   Neugebauer, Witold ^b   Rhaleb, Nour Eddine ^a  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoradiography; Collagen synthesis; Heart; Receptor

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANTIFIBROTIC AGENT; CALCIUM; COLLAGEN; DESAMINOTYROSINE I 125; ENDOTHELIN 1; IODINE 125; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RADIOLIGAND; SERASPENIDE; TETRAPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM CELL LEVEL; CELL CULTURE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; FIBROBLAST CULTURE; HEART CELL CULTURE; HEART MUSCLE; HYPERTENSION; IN VITRO STUDY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BINDING;

ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BINDING, COMPETITIVE; CALCIUM SIGNALING; CELLS, CULTURED; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; FIBROBLASTS; IODINE RADIOISOTOPES; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MYOCARDIUM; NONLINEAR DYNAMICS; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; TIME FACTORS;

EID: 33846955449     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00776.2006     Document Type: Article

References (36)

1. 2+ in endothelin-a-induced MAP kinase phosphorylation, myosin light chain phosphorylation and contraction in rabbit iris sphincter smooth muscle. Cell Signal 16: 609-619, 2004.
2. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Ménard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97: 839-844, 1996.
3. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30: 1015-1019, 1997.
4. Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood 82: 3307-3314, 1993.
5. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-β1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 29: 1947-1958, 1997.
6. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43: 1140-1145, 2004.
7. Chisi JE, Wdzieczak-Bakala J, Riches AC. Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril. Stem Cells 15: 455-460, 1997.
8. Comte L, Lorgeot V, Volkov L, Allegraud A, Aldigier JC, Praloran V. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Invest 27: 788-790, 1997.
9. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219-226, 2002.
10. Eghbali M, Tomek R, Woods C, Bhambi B. Cardiac fibroblasts are predisposed to convert into myocyte phenotype: specific effect of transforming growth factor β. Proc Natl Acad Sci USA 88: 795-799, 1991.
11. Gaudron S, Grillon C, Thierry J, Riches A, Wierenga PK, Wdzieczak-Bakala J. In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation. Stem Cells 17: 100-106, 1999.
12. Grillon C, Lenfant M, Wdzieczak-Bakala J. Optimization of cell culture conditions for the evaluation of the biological activities of the tetrapeptide N-acetyl-ser-asp-lys-pro, a natural hemoregulatory factor. Growth Factors 9: 133-138, 1993.
13. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 140: 4659-4668, 1999.
14. Kanasaki K, Koya D, Sugimoto T, Isono M, Kashiwagi A, Haneda M. N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-β-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol 14: 863-872, 2003.
15. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 86: 779-782, 1989.
16. 1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats. Am J Physiol Renal Physiol 290: F1024-F1033, 2006.
17. Li XC, Carretero OA, Shao Y, Zhuo JL. Glucagon receptor-mediated extracellular signal-regulated kinase 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C. Hypertension 47: 580-585, 2006.
18. Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology Nomenclature of endothelin receptors. Pharmacol Rev 6: 137-142, 1994.
19. Moriguchi Y, Matsubara H, Mori Y, Murasawa S, Masaki H, Maruyama K, Tsutsumi Y, Shibasaki Y, Tanaka Y, Nakajima T, Oda K, Iwasaka T. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-β synthesis via transcriptional and posttranscriptional mechanisms. Circ Res 84: 1073-1084, 1999.
20. A antagonist. In: Peptides 1996. Proceedings of the Twenty-Fourth European Peptide Symposium, September 8-13, 1996, Edinburgh, Scotland, edited by Ramage R, Epton R. European Peptide Society, 1998, p. 677-678.
21. Neugebauer W, Elliott P, Cuello AC, Escher E. Synthesis and immunological evaluation of N-terminal, noncrossreactive tachykinin antigens. J Med Chem 31: 1907-1910, 1988.
22. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE. Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 37: 794-800, 2001.
23. Pokharel S, Rasoul S, Roks AJM, van Leeuwen REW, van Luyn MJA, Deelman LE, Smits JF, Carretero O, van Gilst WH, Pinto YM. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 40: 155-161, 2002.
24. Pradelles P, Frobert Y, Créminon C, Liozon E, Massé A, Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun 170: 986-993, 1990.
25. Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, Brigstock DR, Rhaleb NE. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 22: 593-603, 2004.
26. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 37: 827-832, 2001.
27. Rhaleb NE, Peng H, Yang XP, Liu YH, Mehta D, Ezan E, Carretero OA. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation 103: 3136-3141, 2001.
28. Thierry J, Papet MP, Saez-Servent Plissonneau-Haumont J, Potier P, Lenfant M. Synthesis and activity of NAcSerAspLysPro analogues on cellular interactions between T-cell and erythrocytes in Rosette formation. J Med Chem 33: 2122-2127, 1990.
29. Wang Y, Simonson MS, Pouyssegur J, Dunn MJ. Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells. Biochem J 287: 589-594, 1992.
30. Yang F, Yang XP, Liu YH, Xu J, Cingolani O, Rhaleb NE, Carretero OA. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 43: 229-236, 2004.
31. Zhuo JL, Yamada H, Allen AM, Sun Y, Mendelsohn FAO. Localization and properties of angiotensin converting enzyme and angiotensin II receptors in the heart. In: The Cardiac Renin-Angiotensin System, edited by K. Lindpaintner and D. Ganten. New York: Futura Scientific, 1994, p. 63-88.
32. 1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 39: 634-638, 2002.
33. Zhuo JL, MacGregor DP, Mendelsohn FAO. Presence of angiotensin II AT-2 receptors in the adventitia of human kidney vasculature. Clin Exp Pharmacol Physiol 23: S147-S153, 1996.
34. Zhuo JL, Carretero OA, Peng HM, Regoli D, Neugebauer W, Rhaleb NE. Effects of Ac-SDKP on collagen synthesis are mediated by specific Ac-SDKP receptor binding sites in rat cardiac fibroblasts (Abstract). Hypertension 44: 498, 2004.
35. Zhuo JL, Allen AM, Alcorn D, MacGregor D, Aldred Mendelsohn FAO GP. The distribution of angiotensin II receptors. In: Hypertension: Pathology, Diagnosis, and Management (2nd ed.), edited by Laragh JH, Brenner BM. New York: Raven, 1995, p. 1739-1762.
36. Zhuo JL, Dean R, Maric C, Aldred PG, Harris P, Alcorn D, Mendelsohn FA. Localization and interactions of vasoactive peptide receptors in renomedullary interstitial cells of the kidney. Kidney Int 67: S22-S28, 1998.